MRI to monitor treatment response in rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether an MRI scan done during chemoradiation can help doctors track how rectal cancer treatment is working. It may improve how they measure response early so treatment planning can be better tailored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have confirmed rectal adenocarcinoma and your doctor plans non-surgery chemo-radiation first
- Your overall health is good enough (Karnofsky score 70+ or ECOG 0–1)
- You can sign consent and follow study visits and scan requirements
- Women who could become pregnant must agree to reliable birth control during treatment
- You have access to medical insurance/social security coverage for care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
This trial tests a new way of giving radiation therapy for rectal cancer, using MRI scans to aim the radiation more precisely. It's for people who need chemotherapy and radiation before surgery, and it aims to make treatment more effective while reducing side effects.
This trial uses advanced MRI scans to see how well rectal cancer is responding to radiotherapy. It may help doctors better understand which treatments work best for patients with more advanced disease.
This trial tests whether using MRI scans to guide radiotherapy can improve treatment for people with a certain type of rectal cancer. It focuses on patients whose tumors have not spread to other parts of the body and who have specific tumor features seen on MRI.
This study looks at how an MRI “score” (mrTRG) matches how well locally advanced rectal cancer shrinks after pre-surgery chemotherapy and radiation. The goal is to use MRI results to better predict treatment response and guide care.
This trial uses a special type of MRI scan (called amide proton transfer-weighted imaging) to look at your rectal cancer before and after chemotherapy and/or radiation. The goal is to see if the scan can predict whether the cancer has completely disappeared by the time of surgery, which could help guide future treatment decisions.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.